Table 3.

Results of scenario analyses in which serum fms‐like tyrosine kinase‐1/placental growth factor (sFlt‐1/PlGF) ratio test was used in addition to current diagnostic procedures (test scenario) and in which current diagnostic procedures only were used (no‐test scenario) for guiding management of pre‐eclampsia in a cohort of 1050 women with suspected pre‐eclampsia from the PROGNOSIS study

	Cost (£)
	No‐test scenario	Test scenario	Cost difference (£)	Cost difference per patient (£)
Variation in LOS
Base–case	4 345 382	3 984 200	−361 182	−344
LOS scenario A (halved)	4 024 584	3 729 431	−295 153	−281
LOS scenario B (1.6 days)	3 865 839	3 587 989	−277 849	−265
	Percentage admitted to hospital with:
Variation in number of admissions	Positive test with sFlt‐1/PlGF ratio > 85	Positive test with sFlt‐1/PlGF ratio of 38–85	Negative test with sFlt‐1/PlGF ratio < 38	Cost difference per patient (£)
Base–case	64.75	55.36	1.71	−344
Increase admissions by 10% (proportionately)	71.23	60.90	1.88	−290
Increase admissions by 20% (proportionately)	77.70	66.43	2.05	−235
Increase admissions of patients with a ratio < 38 by 5 percentage points	64.75	55.36	6.71	−139
Increase admissions of patients with a ratio < 38 by 10 percentage points	64.75	55.36	11.71	56
	Cost (£)
Variation in option of retest	No‐test scenario per patient	Test scenario per patient	Cost difference per patient (£)
Base–case	£4138	£3794	−344
Exclude option of retest	£4138	£3756	−382

LOS, length of stay.